These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 34639030)

  • 1. Wee1 Kinase: A Potential Target to Overcome Tumor Resistance to Therapy.
    Esposito F; Giuffrida R; Raciti G; Puglisi C; Forte S
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe.
    De Witt Hamer PC; Mir SE; Noske D; Van Noorden CJ; Würdinger T
    Clin Cancer Res; 2011 Jul; 17(13):4200-7. PubMed ID: 21562035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WEE1 inhibition sensitizes osteosarcoma to radiotherapy.
    PosthumaDeBoer J; Würdinger T; Graat HC; van Beusechem VW; Helder MN; van Royen BJ; Kaspers GJ
    BMC Cancer; 2011 Apr; 11():156. PubMed ID: 21529352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target.
    Ghelli Luserna di Rorà A; Cerchione C; Martinelli G; Simonetti G
    J Hematol Oncol; 2020 Sep; 13(1):126. PubMed ID: 32958072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry.
    Elbæk CR; Petrosius V; Sørensen CS
    Mutat Res; 2020; 819-820():111694. PubMed ID: 32120135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases.
    Schmidt M; Rohe A; Platzer C; Najjar A; Erdmann F; Sippl W
    Molecules; 2017 Nov; 22(12):. PubMed ID: 29168755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer.
    Jin MH; Nam AR; Park JE; Bang JH; Bang YJ; Oh DY
    Cancer Res Treat; 2020 Jan; 52(1):149-166. PubMed ID: 31291716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
    Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD
    Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential properties of mitosis-associated events following CHK1 and WEE1 inhibitor treatments in human tongue carcinoma cells.
    Nojima H; Homma H; Onozato Y; Kaida A; Harada H; Miura M
    Exp Cell Res; 2020 Jan; 386(2):111720. PubMed ID: 31738907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting WEE1 Kinase in Cancer.
    Matheson CJ; Backos DS; Reigan P
    Trends Pharmacol Sci; 2016 Oct; 37(10):872-881. PubMed ID: 27427153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wee1 kinase as a target for cancer therapy.
    Do K; Doroshow JH; Kummar S
    Cell Cycle; 2013 Oct; 12(19):3159-64. PubMed ID: 24013427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 Inhibition.
    Lewis CW; Bukhari AB; Xiao EJ; Choi WS; Smith JD; Homola E; Mackey JR; Campbell SD; Gamper AM; Chan GK
    Cancer Res; 2019 Dec; 79(23):5971-5985. PubMed ID: 31594837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokinetic effects of Wee1 disruption in pancreatic cancer.
    Chang Q; Chandrashekhar M; Ketela T; Fedyshyn Y; Moffat J; Hedley D
    Cell Cycle; 2016; 15(4):593-604. PubMed ID: 26890070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell cycle involvement in cancer therapy; WEE1 kinase, a potential target as therapeutic strategy.
    Vakili-Samiani S; Khanghah OJ; Gholipour E; Najafi F; Zeinalzadeh E; Samadi P; Sarvarian P; Pourvahdani S; Kelaye SK; Hamblin MR; Feizi AAH
    Mutat Res; 2022; 824():111776. PubMed ID: 35247630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Wee1-like protein kinase to treat cancer.
    Stathis A; Oza A
    Drug News Perspect; 2010 Sep; 23(7):425-9. PubMed ID: 20862394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance.
    Zheng H; Shao F; Martin S; Xu X; Deng CX
    Sci Rep; 2017 Mar; 7():43517. PubMed ID: 28262781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Wee1 kinase as a therapeutic approach in Hematological Malignancies.
    Vakili-Samiani S; Turki Jalil A; Abdelbasset WK; Yumashev AV; Karpisheh V; Jalali P; Adibfar S; Ahmadi M; Hosseinpour Feizi AA; Jadidi-Niaragh F
    DNA Repair (Amst); 2021 Nov; 107():103203. PubMed ID: 34390915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinome-wide RNAi screening for mediators of ABT-199 resistance in breast cancer cells identifies Wee1 as a novel therapeutic target.
    Aka Y; Karakas B; Acikbas U; Basaga H; Gul O; Kutuk O
    Int J Biochem Cell Biol; 2021 Aug; 137():106028. PubMed ID: 34171479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma.
    Mir SE; De Witt Hamer PC; Krawczyk PM; Balaj L; Claes A; Niers JM; Van Tilborg AA; Zwinderman AH; Geerts D; Kaspers GJ; Peter Vandertop W; Cloos J; Tannous BA; Wesseling P; Aten JA; Noske DP; Van Noorden CJ; Würdinger T
    Cancer Cell; 2010 Sep; 18(3):244-57. PubMed ID: 20832752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells.
    Mak JP; Man WY; Chow JP; Ma HT; Poon RY
    Oncotarget; 2015 Aug; 6(25):21074-84. PubMed ID: 26025928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.